Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer

被引:0
|
作者
Qingzhu Jia
Wei Wu
Yuqi Wang
Peter B. Alexander
Chengdu Sun
Zhihua Gong
Jia-Nan Cheng
Huaibo Sun
Yanfang Guan
Xuefeng Xia
Ling Yang
Xin Yi
Yisong Y. Wan
Haidong Wang
Ji He
P. Andrew Futreal
Qi-Jing Li
Bo Zhu
机构
[1] Third Military Medical University,Institute of Cancer, Xinqiao Hospital
[2] Chongqing Key Laboratory of Tumor Immunotherapy,Department of Cardiothorathic Surgery, Southwest Hospital
[3] Third Military Medical University,Department of Immunology
[4] Geneplus-Beijing Institute,Biomedical Analysis Center
[5] Duke University Medical Center,Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center
[6] Third Military Medical University,Department of Genomic Medicine
[7] Houston Methodist Research Institute,undefined
[8] University of North Carolina at Chapel Hill,undefined
[9] GeneCast Biotechnology Co.,undefined
[10] Ltd,undefined
[11] The University of Texas MD Anderson Cancer Center,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Combining whole exome sequencing, transcriptome profiling, and T cell repertoire analysis, we investigate the spatial features of surgically-removed biopsies from multiple loci in tumor masses of 15 patients with non-small cell lung cancer (NSCLC). This revealed that the immune microenvironment has high spatial heterogeneity such that intratumoral regional variation is as large as inter-personal variation. While the local total mutational burden (TMB) is associated with local T-cell clonal expansion, local anti-tumor cytotoxicity does not directly correlate with neoantigen abundance. Together, these findings caution against that immunological signatures can be predicted solely from TMB or microenvironmental analysis from a single locus biopsy.
引用
收藏
相关论文
共 50 条
  • [21] Intratumoral hyperthermic chemotherapy injection in peripheral non-small cell lung cancer
    Tohlob, Mohamed A.
    Suliman, Lucy A.
    Elmorsy, Ahmed S.
    Ibrahim, Mohamed A.
    Hewidy, Asem A.
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2020, 14 (01)
  • [22] Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
    Alsdorf, Winfried H.
    Clauditz, Till S.
    Hoenig, Tobias
    Quaas, Alexander
    Sirma, Hueseyin
    Koenig, Alexandra M.
    Izbicki, Jakob
    Sauter, Guido
    Marx, Andreas H.
    Grob, Tobias J.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 94 (01) : 155 - 159
  • [23] Metabolic diversity in human non-small cell lung cancer
    Pei-Hsuan Chen
    Ling Cai
    Hyun Seok Kim
    Rebecca Britt
    Guanghua Xiao
    Michael A White
    John D Minna
    Ralph J DeBerardinis
    Cancer & Metabolism, 2 (Suppl 1)
  • [24] Metabolic diversity in human non-small cell lung cancer
    Chen, Pei-Hsuan
    Cai, Ling
    Kim, Hyun Seok
    Britt, Rebecca
    Xiao, Guanghua
    White, Michael A.
    Minna, John D.
    DeBerardinis, Ralph J.
    CANCER & METABOLISM, 2014, 2
  • [25] Diversity of the angiogenic phenotype in non-small cell lung cancer
    McClelland, Marc R.
    Carskadon, Shannon L.
    Zhao, Liujian
    White, Eric S.
    Beer, David G.
    Orringer, Mark B.
    Pickens, Allan
    Chang, Andrew C.
    Arenberg, Douglas A.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2007, 36 (03) : 343 - 350
  • [26] Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
    Wenfeng Fang
    Haoxuan Jin
    Huaqiang Zhou
    Shaodong Hong
    Yuxiang Ma
    Yaxiong Zhang
    Xiaofan Su
    Longyun Chen
    Yunpeng Yang
    Shengqiang Xu
    Yuwei Liao
    Yuming He
    Hongyun Zhao
    Yan Huang
    Zhibo Gao
    Li Zhang
    Molecular Cancer, 20
  • [27] Mutational signatures in the perspective of tumour mutational burden in patients with non-small cell lung cancer
    Van den Heuvel, G.
    Kroeze, L.
    Ligtenberg, M.
    Grunberg, K.
    von Rhein, D.
    Jansen, E.
    de Voer, R.
    Van den Heuvel, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1217 - S1218
  • [28] Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
    Fang, Wenfeng
    Jin, Haoxuan
    Zhou, Huaqiang
    Hong, Shaodong
    Ma, Yuxiang
    Zhang, Yaxiong
    Su, Xiaofan
    Chen, Longyun
    Yang, Yunpeng
    Xu, Shengqiang
    Liao, Yuwei
    He, Yuming
    Zhao, Hongyun
    Huang, Yan
    Gao, Zhibo
    Zhang, Li
    MOLECULAR CANCER, 2021, 20 (01)
  • [29] TISSUE MICROARRAYS IN NON-SMALL CELL LUNG CANCER (NSCLC): A STUDY OF INTRATUMORAL HETEROGENEITY OF IMMUNOHISTOCHEMICAL MARKER EXPRESSION.
    Poehl, Mette
    Olsen, Karen E.
    Ditzel, Henrik J.
    Hansen, Olfred
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S715 - S715
  • [30] Vaccine and immune cell therapy in non-small cell lung cancer
    Oliveres, Helena
    Caglevic, Christian
    Passiglia, Francesco
    Taverna, Simona
    Smits, Evelien
    Rolfo, Christian
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1602 - S1614